Author Archive | thomas

Trento, Italy, June 26, 2018 – Currently, oncologists and cancer scientists face an abiding problem of major proportion, namely the emergence of resistance of certain cancers-some very common- to any therapy during their course. For some of these tumors, such as melanoma and kidney cancer, immune therapy has shown remarkable effects, but only a small

Mainz, 17. Mai 2018 – Jeder Tumor ist anders. “Krebs entsteht durch individuelle Mutationen”, erklärt Prof. Dr. Ugur Sahin. “Wenn wir uns zum Beispiel den Lungenkrebs verschiedener Patienten anschauen, dann sind diese sehr unterschiedlich. Sie haben im Durchschnitt weniger als fünf Prozent der Mutationen gemeinsam, 95 Prozent sind ganz individuell. Herkömmliche Therapieansätze konzentrieren sich auf

Ghent, Belgium, May 25, 2018 – VIB conference series hosts the MEDICAL BIOTECHNOLOGY focus meeting May 24-25, 2018, in Ghent Belgium. The conference features talks on new disruptive technologies for early diagnosis and more effective therapeutic intervention in established chronic diseases. Dr. Mustafa Diken will share years of experience in his talk “The evolution of

Mainz, May 15-17, 2018 – CIMT 2018 Annual Meeting We are excited about the upcoming Annual Meeting of the Association for Cancer Immunotherapy (CIMT) in our hometown Mainz. Our scientists will be presenting their research in several sessions and look forward to discussing their projects. Thursday, 17 May 2018, Short Talk Session IV Therapeutic Vaccination

Mainz, March 2018 – On March 15th, Prof. Dietmar Zehn from the Technical University of Munich, School of Life Sciences Weihenstephan, will be visiting Mainz in the context of our Seminars in Translational Oncology series (SITO). You are cordially invited to his talk at 5 pm in building 708 of the University Medicine Mainz. The

We are pleased to announce a three-year grant from the Falconwood Foundation, New York, USA, totalling 3 Million Euros. The grant supports the launch of a new research project to identify biomarkers specific for neuroendocrine tumors (NETs) that are crucial for the development of new, personalized immunotherapies to treat NET patients. Further details are announced

In the course of evolution, the immune system has developed sophisticated mechanisms to identify and eliminate invading pathogens and degenerate cells, thereby preventing infection and tumor occurrence. When these mechanisms are ineffective or somehow bypassed, tumors or chronic infections may form. Clarifying the processes leading to ineffective immune defense is the central goal of the

Mainz, 2017-10-25 – TRON scientific advisor Prof. Dr. Dr. Cornelis J. Melief, Leiden, Netherlands, will be awarded with the degree of an honorary medical doctor. Melief will be awarded for his lifetime achievements as a pioneer of tumor immunology, as well as for his commitment and deserts regarding immunological research in Mainz. Further information about

Among nucleic acid-based delivery platforms, self-amplifying RNA (saRNA) vectors are of increasing interest for applications such as transient expression of recombinant proteins and vaccination. Although saRNA is a promising technology, antigen expression from saRNA is limited by the host cells’ innate interferon response. TRON’s Tim Beissert and colleagues show, in an upcoming issue of Human